37 studies found for:    Open Studies | "Wilms Tumor"
Show Display Options
Rank Status Study
21 Recruiting Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia
Intervention: Biological: WT1 peptide vaccine
22 Recruiting Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF;   Biological: Montanide adjuvant + GM-CSF
23 Recruiting Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: busulfan;   Drug: melphalan;   Drug: fludarabine;   Biological: anti-thymocyte globulin (ATG);   Procedure: a T cell depleted stem cell transplant
24 Recruiting CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Biological: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs);   Other: Standard of care
25 Unknown  Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
Conditions: Acute Myelogenous Leukemia;   Myeloid Leukemia in Remission;   Effects of Immunotherapy
Intervention: Biological: Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
26 Unknown  WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention: Biological: WT1 126-134 peptide
27 Recruiting Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Conditions: Leukemia;   Myelodysplastic Syndrome
Intervention: Biological: WT1-sensitized T cells
28 Recruiting Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
Condition: Acute Myeloid Leukemia
Intervention: Biological: DC vaccine
29 Recruiting Collecting and Storing Tissue From Young Patients With Cancer
Condition: Cancer
Interventions: Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
30 Recruiting Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: Biological: basiliximab;   Biological: WT1 126-134 peptide vaccine;   Drug: Montanide ISA 51 VG;   Drug: poly ICLC;   Other: laboratory biomarker analysis
31 Recruiting Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions: Biological: WT1-Sensitized Allogeneic T-Lymphocytes;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis
32 Not yet recruiting Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Conditions: Advanced Pleural Malignant Mesothelioma;   HLA-A*0201 Positive Cells Present;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pleural Malignant Mesothelioma;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pleural Mesothelioma
Interventions: Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes;   Drug: Cyclophosphamide;   Biological: Aldesleukin;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
33 Recruiting Clinical Study of WT2725 in Patients With Advanced Malignancies
Condition: Cancer
Intervention: Biological: WT2725
34 Unknown  Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Conditions: Ewing's Sarcoma;   Soft Tissue Sarcoma;   Hepatoblastoma;   Hodgkin's Disease;   Germ Cell Tumor
Intervention: Drug: High-Dose Chemotherapy with Tandem PBSC Rescue.
35 Unknown  External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Condition: Cancer
Interventions: Drug: indinavir sulfate;   Drug: ritonavir;   Radiation: radiation therapy
36 Unknown  Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Conditions: Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
Interventions: Procedure: management of therapy complications;   Procedure: pain therapy
37 Unknown  Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Condition: Cancer
Interventions: Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: evaluation of cancer risk factors

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-37) Next Page   
Indicates status has not been verified in more than two years